From An Enterprise to an Era
November 17 – 18, 2021 • Harvard Medical School, Boston, MA
The 16th Annual Personalized Medicine Conference at Harvard Medical School will explore how the emergence of COVID-19 as well as the latest developments in science, business and policy are influencing the landscape and outlook for personalized medicine.
It is important that the research, medical, and pharmaceutical communities collaborate to maintain momentum in personalized medicine so that we are able to deliver cutting-edge care and clinical trial opportunities to all patients.”— Carl June, M.D., Richard W. Vague Professor in Immunotherapy, University of Pennsylvania
There is a need for multiple partners to come together to create resources that will benefit all stakeholders. This will require not only data-sharing, but also the ability to collaborate and use these data. No one stakeholder can do it by itself.”— William S. Dalton, Ph.D., M.D., Founder, Executive Chair, M2Gen
The word 'epidemiology' is derived from 'epi' and 'demos' — 'above the people.' It is the science of aggregation, the science of the many. Yet it works most effectively when it moves in step with medicine, the science of the one.”— Siddhartha Mukherjee, M.D., D.Phil., Assistant Professor of Medicine, Columbia University
Amy P. Abernethy, M.D., Ph.D.
Principal Deputy Commissioner
U.S. Food and Drug Administration
Alex J. Carlisle, Ph.D.
National Alliance Against Disparities in Patient Health
Carl June, M.D.
Richard W. Vague Professor in Immunotherapy
University of Pennsylvania
Siddhartha Mukherjee, M.D., D.Phil.
Assistant Professor of Medicine
Shez Partovi, M.D.
Worldwide Lead, Business Development, Healthcare, Life Sciences, Genomics
Amazon Web Services
Michael Pellini, M.D., M.B.A.
Kite, a Gilead company
Senior Vice President, External Affairs